Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors
esmo - Findings from the LITESPARK-011 study
AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.
Related Stories
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 1 month
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 2 months
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 2 months
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cancer Research, Price Transparency, CDC, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine